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The Journal of Clinical Endocrinology & Metabolismrecently published an article by Strand et al. (1). The
authors examined whether serum levels of long-chain
palmitoylcarnitine predict long-term risk for type 2 di-
abetes (T2D) independently of traditional risk factors,
possibly reflecting dysfunctional fatty acid (FA) metab-
olism in patients susceptible to T2D development.We are
concerned about the common trend of using acylcarni-
tine measurements in fasted subjects and subsequent data
interpretations that relate fasted-state acylcarnitine con-
centrations to insulin sensitivity.
In the past 10 years, long-chain acylcarnitine levels have
emerged as markers of insulin resistance and diabetes;
however, in most studies acylcarnitines have been mea-
sured in fasted subjects (1, 2), which is not an appropriate
metabolic state for the characterization of insulin re-
sistance. The fasted and postprandial states are charac-
terized by different intensities of FA metabolism and
different prevailing regulatory mechanisms. Therefore,
measurements of acylcarnitine levels in both states would
help us to better understand the importance of changes in
acylcarnitine concentrations in the context of metabolic
status and the concentrations of other diagnostic markers.
Carnitine palmitoyltransferase 1–mediated long-chain
acylcarnitine synthesis is a step in mitochondrial FA ox-
idation, and various mitochondrial disorders that are
characterized by incomplete FA oxidation cause the ac-
cumulation of long-chain acylcarnitines (3). In rare mi-
tochondrial genetic disorders, ischemia, and the late stages
of heart failure, acylcarnitines accumulate in mitochon-
dria because of a transient or permanent inhibition of FA-
dependent oxidative phosphorylation in the mitochondria
(3, 4). Accordingly, any measured increase in acylcarnitine
concentration has been associated with the incomplete
mitochondrial metabolism of FA. This assumption is
misleading because physiologically, the highest concen-
trations of long-chain acylcarnitines (up to five times
higher than in the fed state) are present during the fasted
and starvation states, when FA metabolism in the heart
and other muscles is significantly increased and pre-
dominates over carbohydrate metabolism (5, 6). In ad-
dition, patients with diabetes but without mitochondrial
dysfunction show elevated concentrations of long-chain
acylcarnitines, accompanied by marked upregulation of
FA oxidation (6). Overall, mitochondrial dysfunction
might be diagnosed by comparing plasma levels of acyl-
carnitine in healthy subjects and patients in the fasted state
but not in the fed state, when extramitochondrial regu-
latory mechanisms become more important. In contrast,
in the fasted state the comparably low level of insulin is
unable to inhibit long-chain acylcarnitine production by
carnitine palmitoyltransferase 1, and measurements of acyl-
carnitines cannot be associated with insulin resistance.
An appropriate state for studies of insulin action, both
physiologically and in various diseases, is after glucose
intake. Because T2D is characterized by insulin resistance,
which causes impaired insulin-mediated glucose uptake in
the peripheral tissues, insulin sensitivity should be evaluated
in the state during which the highest concentration of in-
sulin is present in the circulation or, preferably, during
the transition from the fasted to the fed state, based on
measurements from both states. In healthy subjects in the
fed state, to facilitate glucose metabolism, the increased
concentration of insulin inhibits long-chain acylcarnitine
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production and subsequent FA metabolism. Disturbances
in insulin signaling lead to the inability of insulin to inhibit
long-chain acylcarnitine production in the postprandial
state (5, 6). The limitation of acylcarnitine measurements
after glucose load could be that hyperinsulinemia sup-
presses the synthesis of acylcarnitines, thereby masking
insulin resistance. Therefore, the insulin clampmethodmay
be preferable for evaluating changes in acylcarnitine con-
centrations in response to insulin (6). It must be noted that
plasma long-chain acylcarnitine concentrations are not
associated with whole-body insulin responses but represent
primarily the acylcarnitine content of the heart (7, 8).
Overall, acylcarnitine measurements in the fasted state are
appropriate for the assessment of mitochondrial function,
whereas insulin resistance can be detected only in the
postprandial state after controlled glucose load.
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